Evolution of patient expectations in nAMD through the 21st century

My guest for this episode is Professor Paul Mitchell, Emeritus Professor of Ophthalmology at the University of Sydney, Consultant Ophthalmologist at the Western Sydney Local Health District, and Principal of Sydney West Retina Pty Ltd in Australia. As treatment for neovascular age-related macular degeneration (nAMD) has evolved through the 21st century, so have the expectations of our patients. Paul joins me to chat about how developments in treatment modalities and regimens led to the evolution of patient expectations following diagnosis of nAMD, and what we can expect for our patients in the future.If you enjoyed this episode, try some of our past episodes to hear other retinal experts delve into ways in which we can engage and empower our patients, how to further motivate our patients to be adherent, and how clinic organization can be used to improve adherence and persistence.SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!If you want to know more about the Barometer Program’s efforts towards patient-focused care in nAMD, visit our website: https://www.amdbarometer.org/ Further information on studies mentioned in this episode: Blue Mountains Eye study (https://doi.org/10.1016/S0161-6420(95)30846-9) MARINA study (https://doi.org/10.1056/NEJMoa054481) ANCHOR study (https://doi.org/10.1016/j.ophtha.2008.10.018) LUCAS study (https://doi.org/10.1016/j.ophtha.2014.07.041) ALTAIR study (https://doi.org/10.1007/s12325-020-01236-x) ARIES study (https://doi.org/10.1097/IAE.0000000000003128) HOME study (https://doi.org/10.1016/j.cct.2014.02.003) Algorithm for suspending anti-VEGF treatment in cases of futility (https://doi.org/10.1097/IAE.0000000000002713)June 2024 | MA-PFM-OPHT-ALL-0938-1Speaker disclosures:Professor Anat LoewensteinConsultancy, Research grants: Allergan, Bayer, Beyeonics Surgical, KHB, Novartis, Notal Vision, Oculis, Oxurion, Pres-By, Roche, Sensor, WebMD, XbraneProfessor Paul MitchellConsultancy: Allergan, Bayer, and NovartisThis podcast series is intended for HCPs, and is not intended for UK audiences. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.